



Supplemental Table 1: Survival analysis based on AFP trends.


| Landmark | Response | N (%) | median OS (95%CI) | P |
|---|--|-----------|-------------------|---------|
| Baseline (n=185) | <100 | 123 (66%) | 11.4 (7.9-13.9) | 0.05 |
| | ≥100 | 62 (34%) | 6.5 (5-7.7) | |
| AFP follow-up at any time point (n=101) | Responders (AFP<13 ng/dL) | 12 (12%) | 23.9 (20-124) | <0.0001 |
| | Non / partial responders | 89 (88%) | 6.5 (4.8-7.8) | |
| 1-month (n=101) | Responders (≥50% decrease from baseline) | 49 (48%) | 8.5 (6.5-14.3) | 0.018 |
| | Non-responders (<50% decrease from baseline) | 52 (52%) | 4.8 (3.7-7.7) | |
| 3-month (n=65) | Responders (≥50% decrease from baseline) | 43 (66%) | 13.3 (8.7-17.7) | 0.021 |
| | Non-responders (<50% decrease from baseline) | 22 (34%) | (5.3-8.9) | |




Supplemental Figure 1A: Overall Survival: CP A Main vs. Lobar Vs. Segmental




Supplemental Figure 1B: Overall Survival: CP A Main vs. Lobar/Segmental




Supplemental Figure 2A: Overall Survival: CP B7 Main vs. Lobar vs. Segmental



Supplemental Figure 2B: Overall Survival: CP B7 Main vs. Lobar/Segmental



Supplemental Figure 3A: Overall Survival: CP \geq B8 Main vs. Lobar vs. Segmental



Supplemental Figure 3B: Overall Survival: CP \geq B8 Main vs. Lobar/Segmental